When exposed to tumor cells, these targeted nanoparticles were specifically internalized by EpCAM-expressing tumor cells (e.g., BxPC3, a pancreatic cancer cell), while minimal uptake was observed in cells with low EpCAM expression (e.g., CCRF-CEM, a leukemia cell). This evidence concerns the gene EPCAM and neoplasm.